Chi-jung Wu

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Capsular Tension Ring Use in High Myopic Eyes Undergoing Cataract Surgery: A Systematic Review and Meta-Analysis.

Capsular Tension Ring Use in High Myopic Eyes Undergoing Cataract Surgery: A Systematic Review and Meta-Analysis.

Journal: American journal of ophthalmology

Published: September 10, 2025

Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma.

Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma.

Journal: Liver cancer

Published: August 13, 2025

Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.

Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy.

Journal: Hepatology (Baltimore, Md.)

Published: April 09, 2025

Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.

Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.

Journal: BMC cancer

Published: March 31, 2025

Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.

Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.

Journal: JHEP reports : innovation in hepatology

Published: December 08, 2024

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 28, 2024

Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal Ablation.

Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal Ablation.

Journal: Journal of hepatocellular carcinoma

Published: July 23, 2024

Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation.

Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation.

Journal: Alimentary pharmacology & therapeutics

Published: April 29, 2024

Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

Journal: Journal of hepatology

Published: January 04, 2024

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.

Journal: Liver cancer

Published: August 12, 2023

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment.

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment.

Journal: Viruses

Published: September 29, 2022

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Journal: Journal for immunotherapy of cancer

Published: May 31, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026